Metastatic Hormone Refractory Prostate Cancer Terminated Phase 2 Trials for Docetaxel (DB01248)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00494338Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate CancerTreatment